Additional Data May Clarify Boston’s Watchman Mixed Results, Chances for Approval
Compiled by Michael Manns, Senior Equity Analyst, Jason McGorman, Equity Analyst, Bloomberg Industries and Elizabeth Krutoholow
Additional data on Boston Scientific’s Watchman device may provide clarity on mixed results from the Prevail trial. A preliminary analysis of how effective the device was after 18 months yielded varied results as the study met one of two efficacy endpoints. A limited number of patients have had follow-up thus far, so results from the complete patient population may be different.